An expert workgroup has developed the first appropriate use recommendations (AURs) for real-world use of the antiamyloid donanemab (Kisunla). “The role of appropriate use recommendations are to bridge the gap between clinical trials and clinical practice,” said author Gil Rabinovici, MD, with the Department of Neurology, University of California, San Francisco. “We know that patients...
Tag: <span>Alzheimer’s disease</span>
Post
Taking five or more medications daily can negatively impact older adults with Alzheimer’s disease or related dementias
DREXEL UNIVERSITY Polypharmacy, commonly defined as taking five or more medications daily, is a significant health care concern impacting over 30% of older adults. It is associated with poor health outcomes like falls, medication interactions, hospitalizations and even death. Older adults are at an increased risk of experiencing polypharmacy if they have multiple chronic conditions. While older...
Post
Data suggest ED visit rate 36.1 per 1,000 older adults with Alzheimer’s disease
by Elana Gotkine For adults aged 65 years and older with Alzheimer’s disease, the emergency department visit rate was 36.1 visits per 1,000 adults in 2020 to 2022, according to an October data brief published by the National Center for Health Statistics. Loredana Santo, M.D., M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, and...
Post
Alzheimer’s research: Superspreader fibrils caught in the act
by Andrea Six, Swiss Federal Laboratories for Materials Science and Technology Suspicious protein molecules and fibrils aggregate on nerve cells in dementia. Credit: Empa The treatment of dementia disorders such as Alzheimer’s is still one of the greatest challenges facing modern medicine. In the course of neurodegenerative diseases, certain proteins such as the amyloid β protein...
Post
More Evidence Ties Semaglutide to Reduced Alzheimer’s Risk
A new study provides real-world evidence to support the potential repurposing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), used to treat type 2 diabetes and obesity, for prevention of Alzheimer’s disease (AD). Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their peers who were prescribed any of...
Post
New insights into amyloid β fibril growth offer hope for halting Alzheimer’s progression
by National Institute for Physiological Sciences The process of alternating elongation and pausing of amyloid β (Aβ) fibrils was captured by combining high-speed atomic force microscopy (HS-AFM) and Monte Carlo simulations. The study revealed the mechanism by which the 4396C antibody selectively binds to the “paused state” of fibril growth, effectively inhibiting further elongation of...
Post
Alzheimer’s disease may damage the brain in two phases
SEA-AD study of the MTG and cohort description. Credit: Nature Neuroscience (2024). DOI: 10.1038/s41593-024-01774-5 Alzheimer’s disease may damage the brain in two distinct phases, based on new research using sophisticated brain mapping tools. According to researchers who discovered this new view, the first, early phase happens slowly and silently—before people experience memory problems—harming just a few vulnerable...
Post
Key mechanisms in asymptomatic Alzheimer’s disease brains offer potential protection against cognitive decline
October 3, 2024 by Indiana University Microglia and astrocytic coverage around compact, intermediate, and filamentous amyloid plaques between AD and AsymAD cases. Credit: Acta Neuropathologica (2024). DOI: 10.1007/s00401-024-02775-1Researchers at Indiana University School of Medicine are examining the brains of individuals with asymptomatic Alzheimer’s disease who, despite having amyloid plaque and tau buildup—the primary indicators of...
Post
Could a once-daily pill for seizures also treat Alzheimer’s disease?
A once-a-day pill used to treat seizures could also help treat Alzheimer’s disease, a new study suggests. Image credit: Viktoriya Skorikova/Getty Images. Past research shows that for many people, mild cognitive impairmentTrusted Source can be the first sign of Alzheimer’s disease. About one-third of people who have mild cognitive impairment because of Alzheimer’s disease progresses to dementia within 5 years. “Our studies...
Post
New study traces Alzheimer’s ‘pathology clock’ at unprecedented cellular resolution
Vulnerable neurons during the early stages of Alzheimer’s disease. Credit: Allen Institute Researchers at the Allen Institute for Brain Science, UW Medicine, and Kaiser Permanente Washington Health Research Institute have created the most detailed picture yet of how Alzheimer’s disease (AD) progresses at the cellular level. Using advanced single-cell genomic technologies and novel machine learning...